Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update

Provided By GlobeNewswire

Last update: May 15, 2025

Initiated Phase 2 Seabreeze STAT Asthma and Seabreeze STAT COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations in Asthma and COPD in May 2025; topline data expected in 1H 2026